Výsledky vyhledávání - "F. Caponigro"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Management of recurrent nasopharyngeal carcinoma: current perspectives

Autor: F, Perri, G, Della Vittoria Scarpati, F, Caponigro, F, Ionna, F, Longo, S, Buonopane, P, Muto, M, Di Marzo, S, Pisconti, R, Solla

Publikováno v: OncoTargets and Therapy, Vol Volume 12, Pp 1583-1591 (2019)
OncoTargets and therapy

F Perri,1 G Della Vittoria Scarpati,2 F Caponigro,1 F Ionna,3 F Longo,3 S Buonopane,4 P Muto,4 M Di Marzo,5 S Pisconti,6 R Solla7 1Head and Neck/Sarcoma Medical Oncology Unit, INT IRCCS G Pascale, Naples, Italy; 2Medical Oncology Unit, ASL NA3, Hospi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::96e0374846bae4be5a6321c9cab06fe2
https://www.dovepress.com/management-of-recurrent-nasopharyngeal-carcinoma-current-perspectives-peer-reviewed-article-OTT

Zobrazit plný text záznamu

A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study

Publikováno v: Diagnostics; Volume 11; Issue 6; Pages: 979
Diagnostics
Diagnostics, Vol 11, Iss 979, p 979 (2021)

Baseline clinical prognostic factors for recurrent and/or metastatic (RM) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy are lacking. CT-based radiomics may provide additional prognostic information. A total of 85 patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850e79c09c3bcb307d4eb321b1e273b8
https://doi.org/10.3390/diagnostics11060979

Zobrazit plný text záznamu

Plný text ve formátu HTML

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 28(11)

Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin with/without paclitaxel (CetCis versus CetCisPac) in patients with recurrent and/or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104f14f21fd70ed5f5b3eaffc4d9978c
https://pubmed.ncbi.nlm.nih.gov/28950305

Zobrazit plný text záznamu

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

Autor: M. Schena, S. Crippa, A. Petroccione, S. Comis, Carlo Barone, Steven D. Weitman, R. MacArthur, Marco Merlano, G. Fornari, F. Fiorentini, Domenica Lorusso, M. G. Jannuzzo, Mario Airoldi, F. Caponigro

Publikováno v: Cancer Chemotherapy and Pharmacology. 66:389-394

Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a363b84f7228600856eee4442857cd4d
https://doi.org/10.1007/s00280-009-1175-6

Zobrazit plný text záznamu

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

Autor: Chris Twelves, Alan Anthoney, F. Caponigro, AS Govaerts, A. Milano, Sandrine Marreaud, Denis Lacombe, J. Bauer

Publikováno v: European Journal of Cancer. 45:48-55

The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward. Bortezomib is an inhibitor of p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8f51f97ea8dab600ea1793b706f610
https://doi.org/10.1016/j.ejca.2008.08.011

Zobrazit plný text záznamu

Phase II study of E7070 in patients with metastatic melanoma

Autor: Benoit Baron, M. Ravic, Steinar Aamdal, John F. Smyth, Thierry Lesimple, C. Dittrich, N. Djurasinovic, Martin Gore, Ahmad Awada, Pierre Fumoleau, Cornelis J. A. Punt, Patrick Schöffski, F. Caponigro

Publikováno v: Annals of Oncology, 16, 158-61
Annals of oncology, 16(1), 158-161. Oxford University Press
Annals of Oncology, 16, 1, pp. 158-61

Contains fulltext : 49133ravic.pdf (Publisher’s version ) (Closed access) E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b204f0a729784d4cbf3e8915f32924
https://hdl.handle.net/2066/49133

Zobrazit plný text záznamu

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

Autor: Sabine Adank, Simon van Belle, Pax Willemse, Jantien Wanders, Roberto Sorio, Jan Demol, F Caponigro, Rosa Tambaro, Anne Floquet, Angela Capriati, Alessandro Comandini

Publikováno v: Investigational New Drugs. 23:85-89

Background: Sabarubicin (MEN-10755) is a third generation anthracycline, with a remarkable antitumor activity in human tumor xenografts, including doxorubicin-resistant tumors. Phase I studies have shown that myelosuppression is the main toxicity of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f0a194b1f6a7743b523c20a31a0960
https://doi.org/10.1023/b:drug.0000047110.36382.45

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání